9 Top AI Drug Discovery Software Tools in 2026

Key takeaways

• AI drug discovery software supports different stages, from target identification and protein design to molecular modeling and virtual screening.

• Some platforms are ready-to-use applications; others provide infrastructure or models that research teams configure themselves.

• Converge Bio ranks first for its solutions across target discovery, antibody design, protein optimization, and biomarker discovery.

• AI-generated predictions help researchers prioritize experiments, but laboratory and clinical validation remain essential.

• Compare platforms by modality, data requirements, workflow fit, and how experimental results feed back into future analysis.

AI drug discovery tools can help research teams analyze biological data, generate or prioritize candidate molecules, and plan experiments. The category includes both specialized software and broader platforms that connect computational work with laboratory workflows. Their capabilities are not interchangeable: a tool for antibody design may not support small-molecule screening, while a model-development platform may require substantial in-house computational expertise.

At a glance

1. Converge Bio — applies generative AI across target discovery, antibody design, protein optimization, and biomarker discovery.
2. Schrödinger LiveDesign — connects molecular modeling, experimental data, and collaborative compound design.
3. Insilico Medicine Pharma.AI — offers tools across biology, chemistry, and clinical development.
4. Amazon Bio Discovery — supports AI-guided antibody design with integrated laboratory testing workflows.
5. NVIDIA BioNeMo — provides models, frameworks, and services for building and deploying biological AI.
6. AWS HealthOmics for Drug Discovery — supports scalable biological data processing and computational research workflows.
7. Helical Virtual Lab — evaluates and adapts biological foundation models for target and biomarker discovery.
8. XtalPi ID4Inno — combines AI, physics-based modeling, and automated experimentation for small-molecule research.
9. Atomwise AtomNet — applies deep learning to structure-based small-molecule discovery.

How AI drug discovery platforms fit into research workflows

AI tools can contribute at several points in drug discovery, but each point has different data and validation needs.

• Target discovery: Analyze biological evidence to identify and prioritize potential disease targets.

• Molecular design: Generate or refine candidate proteins, antibodies, or small molecules.

• Candidate evaluation: Predict properties such as binding, stability, or developability to help prioritize experiments.

• Experimental feedback: Compare predictions with lab results and use that evidence to refine future work.

A platform may cover one stage or connect several. Before comparing products, define the biological modality, research question, and available data. Also distinguish software that provides models or workflows from services that include scientific collaboration or wet-lab work.

9 top AI drug discovery software tools

1. Converge Bio

Converge Bio develops generative AI solutions for biotech and pharmaceutical research teams. Its models are trained on biological data spanning DNA, RNA, and protein sequences, with applications across several drug development stages. The company’s deployed solutions include target discovery, antibody design, protein manufacturing optimization, and biomarker discovery.

For antibody research, ConvergeAB can generate and screen large sets of candidate sequences, then score them on properties such as affinity, developability, epitope specificity, humanization, and structural fit. The platform provides visual outputs and candidate profiles to help scientists compare options before synthesis. Converge Bio also describes working with customers through experimental validation, connecting computational predictions with wet-lab results.

Converge Bio ranks first because its offering spans multiple discovery workflows while focusing on outputs scientists can evaluate and test. Its solutions-first approach may suit teams that want AI models applied to defined research problems, rather than a general-purpose modeling environment they must build around themselves. Teams should still confirm which modules align with their target, modality, data, and validation requirements.

Relevant capabilities include:

• Generative AI models for biological sequence data
• Solutions for target and biomarker discovery
• Antibody candidate generation and scoring
• Protein optimization and experimental validation support

2. Schrödinger LiveDesign

Schrödinger LiveDesign is a collaborative molecular design environment that brings computational predictions and experimental data into a shared workspace. It supports small- and large-molecule research, giving discovery teams a place to compare compounds, inspect model outputs, and coordinate design decisions. Its software connects with Schrödinger’s physics-based modeling and machine-learning capabilities.

For small-molecule programs, teams can use LiveDesign to organize design hypotheses, predict molecular properties, track compounds, and prioritize synthesis decisions. For biologics, it supports workflows involving sequence, structure, candidate analysis, and lead selection. The platform also provides APIs for integrating in-house and third-party technologies, and can support collaboration with external partners such as CROs.

Relevant capabilities include:

• Shared project workspace for experimental and computational data
• Molecular modeling and property prediction
• Workflows for small molecules and biologics
• Integration options for models and external research tools

3. Insilico Medicine Pharma.AI

Pharma.AI is Insilico Medicine’s suite of generative AI software for research across biology, chemistry, and clinical development. Its tools include PandaOmics for target discovery, Generative Chemistry for molecule design, and inClinico for clinical trial prediction. Additional tools support areas such as ADMET prediction, molecular simulation, and scientific research.

This modular structure lets teams select tools for particular discovery and development tasks. Researchers can use the platform to generate hypotheses, prioritize targets, propose novel molecules, and analyze properties that affect candidate selection. Insilico also uses Pharma.AI internally to advance its own therapeutic pipeline, so the platform sits alongside a drug-development operation rather than functioning solely as an independent software vendor.

Relevant capabilities include:

• Target discovery and biological hypothesis generation
• Generative small-molecule design
• ADMET prediction and chemistry workflows
• Clinical development and trial analysis tools

4. Amazon Bio Discovery

Amazon Bio Discovery is an AI application focused on antibody design and evaluation. It gives researchers access to a catalog of biological AI models, including options to upload custom or licensed models. AI agents can help users select models, configure experiments, and assess candidate sequences before moving selected designs to laboratory testing.

The platform connects in-silico experiments with integrated lab partners. Researchers can send candidates for synthesis or testing and receive results back in the application, creating a lab-in-the-loop workflow. The returned data can be compared with predictions and used to refine subsequent experiments. Amazon Bio Discovery also provides tools for computational biologists to create reusable pipelines, while bench scientists can run workflows through a visual interface.

Relevant capabilities include:

• Catalog of biological AI models for antibody research
• AI-guided model selection and experiment configuration
• Candidate ranking and evaluation
• Connections to laboratory partners and feedback workflows

5. NVIDIA BioNeMo

NVIDIA BioNeMo is a developer platform for building, customizing, and deploying biological AI models. It includes pretrained biomolecular models, development frameworks, and inference services for tasks such as protein structure prediction, molecular generation, property prediction, and molecular docking. Teams can use it to adapt models to proprietary data or integrate model capabilities into their own research applications.

BioNeMo is intended for organizations with computational biology and engineering resources. The framework supports model training and fine-tuning, while BioNeMo NIM microservices provide packaged model inference for deployment in cloud or on-premises environments. NVIDIA has also expanded the ecosystem with agent-callable tools for workflows such as virtual screening, protein design, and genomics analysis.

Relevant capabilities include:

• Pretrained models for biological and molecular research
• Tools for training and fine-tuning models
• Inference microservices for deployment
• Support for custom AI applications and workflows

6. AWS HealthOmics for Drug Discovery

AWS HealthOmics for Drug Discovery provides managed compute and workflow infrastructure for biological research. It helps teams run biological foundation models and bioinformatics workflows without managing all the underlying compute resources themselves. Researchers can experiment with models for areas such as protein folding, molecular design, and drug-target interaction prediction.

HealthOmics is infrastructure-oriented, so it is not a turnkey drug candidate design application. Teams should consider how much computational workflow development they can support, what data types they need to process, and how the service fits their cloud architecture and governance requirements.

Relevant capabilities include:

• Managed compute for biological AI and bioinformatics workflows
• Support for common scientific workflow languages
• Access to biological foundation models
• Provenance tracking for reproducible analyses

7. Helical Virtual Lab

Helical Virtual Lab supports target identification and biomarker discovery using biological foundation models. The platform is designed to help research teams evaluate models against their own scientific questions, adapt models to proprietary data, and combine them into computational workflows. Helical also offers an open-source framework for accessing and fine-tuning biological models.

Teams should evaluate how the platform supports their data modalities, therapeutic areas, and evidence requirements. Target discovery predictions remain hypotheses for follow-up; a model’s retrospective performance does not establish that a novel target is causally relevant or therapeutically actionable.

Relevant capabilities include:

• Biological foundation model evaluation
• Model adaptation using proprietary data
• Target and biomarker discovery workflows
• In-silico experiments and candidate prioritization

8. XtalPi ID4Inno

XtalPi’s ID4Inno platform applies AI and physics-based modeling to small-molecule drug discovery. Its approach combines computational methods with automated experimentation and domain expertise. The platform is designed to explore chemical space, generate candidate molecules, and support lead identification and optimization.

When evaluating ID4Inno, clarify the target types, chemistry workflows, and experimental capabilities available for a specific program. Also establish how candidate selection criteria are defined and how prediction quality is assessed against wet-lab data.

Relevant capabilities include:

• AI-assisted small-molecule design and screening
• Physics-based modeling
• Automated experimentation and data feedback
• Lead identification and optimization workflows

9. Atomwise AtomNet

Atomwise’s AtomNet applies deep learning to structure-based small-molecule discovery. It uses protein structure information to help predict molecular interactions and identify compounds for follow-up. The company works with research partners and also advances its own small-molecule pipeline, so access may be structured around collaborations rather than a self-serve software subscription.

As with other AI drug discovery software, virtual screening can help narrow a search space but does not establish biological activity or therapeutic potential. Teams should ask how candidate ranking is validated, what experimental support is included in a collaboration, and what data or target information is required to begin.

Relevant capabilities include:

• Structure-based small-molecule screening
• Deep-learning predictions for protein-ligand interactions
• Candidate prioritization for experimental follow-up
• Research collaboration options

How to compare AI drug discovery tools by modality

A platform’s value depends on whether it supports the biological modality and research stage your team needs. Before comparing individual features, map the project’s inputs and outputs.

• Small molecules: Review structure-based design, virtual screening, property prediction, and synthesis planning.
• Antibodies and proteins: Check sequence generation, structure modeling, affinity, stability, and developability assessment.
• Target and biomarker discovery: Compare supported omics data, evidence integration, model benchmarking, and candidate ranking.
• Lab-in-the-loop research: Confirm whether experiments are coordinated through the platform or require separate providers and integrations.
• Model development: Determine whether your team can train or adapt models, or needs ready-to-run workflows.

This comparison keeps teams from treating broad claims about “AI drug discovery” as evidence that a platform supports a specific program.

What to validate before acting on AI-generated candidates

Predictions should guide experiments, not replace them. Establish how the team will evaluate a platform’s outputs before using them to prioritize substantial research resources.

• Define measurable criteria for a useful candidate, such as binding, selectivity, stability, or synthesis feasibility.
• Test predictions against a relevant baseline and held-out or newly generated data.
• Record model versions, input data, parameters, and experimental outcomes.
• Check whether the platform can explain why candidates were ranked or filtered.
• Plan wet-lab validation for prioritized candidates and feed results back into analysis.

For each project, agree on who reviews model outputs, who approves experiments, and how conflicting evidence is handled. These steps help teams interpret AI results within the limits of the data and models used.

FAQs

What is AI drug discovery software?

AI drug discovery software applies machine learning, generative models, or biological foundation models to research tasks such as target identification, molecular design, virtual screening, and candidate evaluation. Some products are ready-to-use applications, while others are development frameworks or computational infrastructure. They help researchers prioritize work, but experimental studies remain necessary to assess candidate behavior.

Can AI drug discovery tools replace laboratory experiments?

No. AI can narrow candidate lists, suggest molecular designs, or identify biological patterns, but predictions need experimental testing. Lab results help determine whether a candidate has the expected properties and can also reveal gaps in a model’s predictions. Some platforms connect computational workflows with laboratory partners, while others require teams to arrange validation separately.

Which AI platform is strongest for antibody discovery?

The answer depends on the workflow. Converge Bio focuses on generating and scoring antibody candidates, while Amazon Bio Discovery connects model-guided antibody design with laboratory testing workflows. NVIDIA BioNeMo provides components for teams building their own protein design systems. Compare target support, developability criteria, integrations, and experimental validation options.

What data do AI drug discovery platforms require?

Requirements vary by task. Target discovery may use omics, literature, or experimental data; molecular design may require target structures, sequences, assay results, or compound data. Teams should check input formats, minimum data quality, proprietary data handling, and whether models can be adapted to internal datasets. Data provenance and version tracking are also important.